Literature DB >> 23359313

Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors.

Jessica A Davila1, Jennifer R Kramer, Zhigang Duan, Peter A Richardson, Gia L Tyson, Yvonne H Sada, Fasiha Kanwal, Hashem B El-Serag.   

Abstract

UNLABELLED: The delivery of treatment for hepatocellular carcinoma (HCC) could be influenced by the place of HCC diagnosis (hospitalization versus outpatient), subspecialty referral following diagnosis, as well as physician and facility factors. We conducted a study to examine the effect of patient and nonpatient factors on the place of HCC diagnosis, referral, and treatment in Veterans Administration (VA) hospitals in the United States. Using the VA Hepatitis C Clinical Case Registry, we identified hepatitis C virus (HCV)-infected patients who developed HCC during 1998-2006. All cases were verified and staged according to Barcelona Clinic Liver Cancer (BCLC) criteria. The main outcomes were place of HCC diagnosis, being seen by a surgeon or oncologist, and treatment. We examined factors related to these outcomes using hierarchical logistic regression. These factors included HCC stage, HCC surveillance, physician specialty, and facility factors, in addition to risk factors, comorbidity, and liver disease indicators. Approximately 37.2% of the 1,296 patients with HCC were diagnosed during hospitalization, 31.0% were seen by a surgeon or oncologist, and 34.3% received treatment. Being seen by a surgeon or oncologist was associated with surveillance (adjusted odds ratio [aOR] = 1.47; 95% CI: 1.20-1.80) and varied by geography (1.74;1.09-2.77). Seeing a surgeon or oncologist was predictive of treatment (aOR = 1.43; 95% CI: 1.24-1.66). There was a significant increase in treatment among patients who received surveillance (aOR = 1.37; 95% CI: 1.02-1.71), were seen by gastroenterology (1.65;1.21-2.24), or were diagnosed at a transplant facility (1.48;1.15-1.90).
CONCLUSION: Approximately 40% of patients were diagnosed during hospitalization. Most patients were not seen by a surgeon or oncologist for treatment evaluation and only 34% received treatment. Only receipt of HCC surveillance was associated with increased likelihood of outpatient diagnosis, being seen by a surgeon or oncologist, and treatment.
Copyright © 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2013        PMID: 23359313      PMCID: PMC4046942          DOI: 10.1002/hep.26287

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  32 in total

1.  Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan.

Authors:  S Arii; Y Yamaoka; S Futagawa; K Inoue; K Kobayashi; M Kojiro; M Makuuchi; Y Nakamura; K Okita; R Yamada
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

2.  Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience.

Authors:  M F Yuen; C C Cheng; I J Lauder; S K Lam; C G Ooi; C L Lai
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

3.  Method to develop health care peer groups for quality and financial comparisons across hospitals.

Authors:  Margaret M Byrne; Christina N Daw; Harlan A Nelson; Tracy H Urech; Kenneth Pietz; Laura A Petersen
Journal:  Health Serv Res       Date:  2008-11-04       Impact factor: 3.402

4.  Geographic variation, physician characteristics, and diabetes care disparities in a metropolitan area, 2003-2004.

Authors:  Jeff McGinn; Cathy Davis
Journal:  Diabetes Res Clin Pract       Date:  2006-01-19       Impact factor: 5.602

5.  Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience).

Authors:  Franco Trevisani; Stefania De Notariis; Gianludovico Rapaccini; Fabio Farinati; Luisa Benvegnù; Marco Zoli; Gian Luca Grazi; Poggio Paolo Del; NolfoMariaAnna Di; Mauro Bernardi
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

6.  Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients?

Authors:  Ernest Wen-Ruey Yu; Wei-Chu Chie; Tony Hsiu-Hsi Chen
Journal:  Cancer J       Date:  2004 Sep-Oct       Impact factor: 3.360

7.  Survival in hepatitis C and HIV co-infection: a cohort study of hospitalized veterans.

Authors:  Hashem B El-Serag; Thomas P Giordano; Jennifer Kramer; Peter Richardson; Julianne Souchek
Journal:  Clin Gastroenterol Hepatol       Date:  2005-02       Impact factor: 11.382

8.  Utilization of screening for hepatocellular carcinoma in the United States.

Authors:  Jessica A Davila; Allan Weston; Walter Smalley; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2007-09       Impact factor: 3.062

9.  Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?

Authors:  Franco Trevisani; Valentina Santi; Annagiulia Gramenzi; Maria Anna Di Nolfo; Paolo Del Poggio; Luisa Benvegnù; Gianludovico Rapaccini; Fabio Farinati; Marco Zoli; Franco Borzio; Edoardo Giovanni Giannini; Eugenio Caturelli; Mauro Bernardi
Journal:  Am J Gastroenterol       Date:  2007-07-07       Impact factor: 10.864

10.  Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors.

Authors:  Fasiha Kanwal; Tuyen Hoang; Brennan M R Spiegel; Seth Eisen; Jason A Dominitz; Allen Gifford; Mathew Goetz; Steven M Asch
Journal:  Hepatology       Date:  2007-12       Impact factor: 17.425

View more
  25 in total

1.  Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer.

Authors:  M Walker; H B El-Serag; Y Sada; S Mittal; J Ying; Z Duan; P Richardson; J A Davila; F Kanwal
Journal:  Aliment Pharmacol Ther       Date:  2016-01-19       Impact factor: 8.171

2.  Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma.

Authors:  Amit G Singal; Akbar K Waljee; Nishant Patel; Emerson Y Chen; Jasmin A Tiro; Jorge A Marrero; Adam C Yopp
Journal:  J Natl Compr Canc Netw       Date:  2013-09-01       Impact factor: 11.908

3.  Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival.

Authors:  Manuel Hernández-Guerra; Alejandro Hernández-Camba; Juan Turnes; Luis Martin Ramos; Laura Arranz; José Mera; Javier Crespo; Enrique Quintero
Journal:  United European Gastroenterol J       Date:  2015-06       Impact factor: 4.623

4.  No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis.

Authors:  Andrew M Moon; Noel S Weiss; Lauren A Beste; Feng Su; Samuel B Ho; Ga-Young Jin; Elliott Lowy; Kristin Berry; George N Ioannou
Journal:  Gastroenterology       Date:  2018-07-05       Impact factor: 22.682

5.  Differences in Physician Referral Drive Disparities in Surgical Intervention for Hepatocellular Carcinoma: A Retrospective Cohort Study.

Authors:  Alexis P Chidi; Cindy L Bryce; Larissa Myaskovsky; Michael J Fine; David A Geller; Douglas P Landsittel; Allan Tsung
Journal:  Ann Surg       Date:  2016-02       Impact factor: 12.969

6.  Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C.

Authors:  Charlotte E Costentin; Philippe Sogni; Bruno Falissard; Jean-Claude Barbare; Noelle Bendersky; Olivier Farges; Nathalie Goutte
Journal:  Dig Dis Sci       Date:  2019-07-25       Impact factor: 3.199

Review 7.  Prognostic and clinicopathological significance of MACC1 expression in hepatocellular carcinoma patients: a meta-analysis.

Authors:  Da-Wei Sun; Ying-Yi Zhang; Yue Qi; Gui-Qi Liu; Yu-Guo Chen; Jian Ma; Guo-Yue Lv
Journal:  Int J Clin Exp Med       Date:  2015-04-15

8.  Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma.

Authors:  Edith Y Ho; Myrna L Cozen; Hui Shen; Robert Lerrigo; Erica Trimble; James C Ryan; Carlos U Corvera; Alexander Monto
Journal:  HPB (Oxford)       Date:  2014-01-28       Impact factor: 3.647

Review 9.  Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma.

Authors:  Alessandro Cucchetti; Fabio Piscaglia; Matteo Cescon; Giorgio Ercolani; Antonio Daniele Pinna
Journal:  World J Gastroenterol       Date:  2013-07-14       Impact factor: 5.742

10.  Access to Subspecialty Care And Survival Among Patients With Liver Disease.

Authors:  Jessica L Mellinger; Stephanie Moser; Deborah E Welsh; Matheos T Yosef; Tony Van; Heather McCurdy; Mina O Rakoski; Richard H Moseley; Lisa Glass; Akbar K Waljee; Michael L Volk; Anne Sales; Grace L Su
Journal:  Am J Gastroenterol       Date:  2016-03-29       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.